Rita J. Balice-Gordon net worth and biography

Rita Balice-Gordon Biography and Net Worth

Rita Balice-Gordon, Ph.D. is the Chief Executive Officer of Muna Therapeutics, a biotech company focused on developing novel therapeutics for patients with neurodegenerative diseases. Previously, Dr. Balice-Gordon served in senior leadership roles at Sanofi, Inc., most recently as Global Head of Rare and Neurological Diseases.

Prior to joining Sanofi, Dr. Balice-Gordon led the psychiatry and pain drug discovery portfolios as Vice President in the Neuroscience and Pain Research Unit at Pfizer, Inc. Earlier in her career, Dr. Balice-Gordon was Professor of Neuroscience and Chair of the Neuroscience Graduate Group at the University of Pennsylvania Perelman School of Medicine, where she currently holds an appointment as Adjunct Professor in the Department of Neuroscience.

Dr. Balice-Gordon has authored more than 100 scientific papers, received numerous accolades for her work in the field of neuroscience, including election as a Fellow of AAAS, and has chaired or served on many NIH, national and international committees. She received her B.A in Biological Sciences from Northwestern University and her Ph.D. in Neurobiology from the University of Texas at Austin, and she completed a postdoctoral fellowship at Washington University School of Medicine in St. Louis.

What is Rita J. Balice-Gordon's net worth?: The estimated net worth of Rita J. Balice-Gordon is at least $2.47 million as of December 5th, 2025. Balice-Gordon owns 52,629 shares of Collegium Pharmaceutical stock worth more than $2,469,353 as of February 5th. This net worth evaluation does not reflect any other assets that Balice-Gordon may own. Learn More about Rita J. Balice-Gordon's net worth.
How do I contact Rita J. Balice-Gordon?: The corporate mailing address for Balice-Gordon and other Collegium Pharmaceutical executives is 100 Technology Center Drive, Stoughton MA, 02072. Collegium Pharmaceutical can also be reached via phone at (781) 713-3699 and via email at [email protected]. Learn More on Rita J. Balice-Gordon's contact information.
Has Rita J. Balice-Gordon been buying or selling shares of Collegium Pharmaceutical?: Rita J. Balice-Gordon has not been actively trading shares of Collegium Pharmaceutical over the course of the past ninety days. Most recently, Rita J. Balice-Gordon sold 3,650 shares of the business's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $47.03, for a transaction totalling $171,659.50. Following the completion of the sale, the director now directly owns 52,629 shares of the company's stock, valued at $2,475,141.87. Learn More on Rita J. Balice-Gordon's trading history.
Who are Collegium Pharmaceutical's active insiders?: Collegium Pharmaceutical's insider roster includes Rita Balice-Gordon (Director), Garen Bohlin (Director), Joseph Ciaffoni (Pres), Joseph Ciaffoni (CEO), Scott Dreyer (EVP), John Freund (Director), Michael Heffernan (Director), Shirley Kuhlmann (EVP), Gino Santini (Director), Thomas Smith (EVP), Colleen Tupper (CFO), and Colleen Tupper (Exec. VP & CFO ). Learn More on Collegium Pharmaceutical's active insiders.
Are insiders buying or selling shares of Collegium Pharmaceutical?: During the last year, insiders at the specialty pharmaceutical company sold shares 15 times. They sold a total of 195,336 shares worth more than $6,856,675.54. The most recent insider tranaction occured on December, 8th when EVP Scott Dreyer sold 17,600 shares worth more than $847,792.00. Insiders at Collegium Pharmaceutical own 2.5% of the company. Learn More about insider trades at Collegium Pharmaceutical.
Information on this page was last updated on 12/8/2025.

Rita J. Balice-Gordon Insider Trading History at Collegium Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/5/2025	Sell	3,650	$47.03	$171,659.50	52,629

Rita J. Balice-Gordon Buying and Selling Activity at Collegium Pharmaceutical

Collegium Pharmaceutical Company Overview

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Today's Range

Now: $46.92

$46.59

$49.31

50 Day Range

MA: $47.38

$44.82

$49.84

2 Week Range

Now: $46.92

$23.23

$50.79

Volume

416,797 shs

Average Volume

456,297 shs

Market Capitalization

$1.48 billion

P/E Ratio

29.14

Dividend Yield

N/A

Beta

0.64